Medical Communications

Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review …

The FDA is set to refocus its efforts in combating the United States’ opioid crisis. Speaking at a meeting of …

One of the largest petitions ever to have gone before UK parliament, after it attracted 823,349 signatures, brought about the …

A new study commissioned by the Department of Health and Social Care has revealed that 237 million medication errors are …

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

One of the key challenges facing the treatment of cancer is knowing whether a particular drug will work with an …

Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …

Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the …

A year to the day that the FDA unveiled its Final Rule, which sees organisation given 13 months from clinical …

Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …

After a 20-hour debate, Greek parliament has voted in favour of investigating 10 politicians named as part of an investigation …

Pharmafocus talks to John Ellwood about the challenges of being diagnosed with multiple myeloma and how having a strong support …

Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …

Researchers at the Roswell Park Comprehensive Cancer Centre in New York have published findings indicating that ovarian cancer risk may …